Table 2 Treatment characteristics after baseline PSMA-PET/CT.
MDRT group | Control group | |
|---|---|---|
PSA level 6 months after PSMA-PET | 3.25 ng/ml (range: 0.01–27.07) | 7.80 ng/ml (range:0.01–60.0) |
Subsequent therapy after PSMA-PET | ||
Abiraterone | n = 20 (58.82%) | n = 9 (42.86%) |
Enzalutamide | n = 14 (41.18%) | n = 8 (38.10%) |
Abiraterone and Enzalutamide | n = 9 (26.47%) | n = 4 (19.05%) |
Apalutamid | n = 1 (2.94%) | n = 1 (4.76%) |
Not recieved ARPI | n = 8 (23.53%) | n = 7 (33.33%) |
Zoledron acid/ Denosumab | n = 9 (26.47%) | n = 8 (38.10%) |
Docetaxel | n = 12 (35.29%) | n = 8 (38.10%) |
Cabazitaxel | n = 8 (23.53%) | n = 5(23.80%) |
Palliative RT (a.e. bone metastasis during further follow up) | n = 6 (17.65%) | n = 5 (23.80%) |
Radium | n = 6 (17.65%) | n = 0 |
PSMA-directed Lutetium-177 radio-ligand therapy | n = 2 (5.88%) | n = 5 (23.80%) |
Subsequent radiotherapy after second PET | n = 24 (70.59%) | |
Symptomatic metastasis in the course | n = 3 (8.8%) | n = 4 (19.05%) |
